Dipivefrin
A prodrug of epinephrine (adrenaline) used as eye drops to lower intraocular pressure in open-angle glaucoma. After penetrating the eye, it is converted to epinephrine, which reduces fluid production and increases drainage within the eye. The prodrug form penetrates the cornea more effectively than epinephrine itself.
Masse moléculaire
351,4000 g/mol
LogP
2,90
TPSA
84,90 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Structure 2D
Cite this structure
Embed this structure
SMILES
CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
InChI
InChI=1S/C19H29NO5/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6/h8-10,13,20-21H,11H2,1-7H3
Molecular Formula
C19H29NO5
HBD / HBA
2 / 6
Liaisons Rotatives
9
Atomes Lourds
25
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A prodrug of epinephrine (adrenaline) used as eye drops to lower intraocular pressure in open-angle glaucoma. After penetrating the eye, it is converted to epinephrine, which reduces fluid production and increases drainage within the eye. The prodrug form penetrates the cornea more effectively than epinephrine itself.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Dipivefrin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201262. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3105. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dipivefrin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dipivefrin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dipivefrin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dipivefrin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dipivefrin"></drugfyi-drug>